Magnum

E-Brake

F
N+ Score47
Vitamins & MineralsServing: 3 Capsule(s)Type: Other Combinations

Magnum E-Brake is an 'Other Combinations' supplement containing 7 ingredients aimed at various physiological processes. Key ingredients include Brassaiopsis glomerulata (166.67mg), Acacetin (33.30mg), Hesperidin (33.33mg), Pygeum Bark Extract (33.30mg), and Stinging Nettle leaf extract (30.00mg), alongside Vitamin D3 (133.33 IU). This product received an N+ Score of 47, earning an 'F' grade, indicating a below-average quality assessment. The analysis found no ingredients at clinically studied doses, and Vitamin D3 is notably underdosed at 133.33 IU compared to common recommendations. This product may appeal to individuals exploring a multi-ingredient formula, but the low dosages of key components are a significant limitation.

About This Product

E-Brake by Magnum is a vitamins & minerals supplement containing 7 active ingredients. It has earned an N+ Score of 47/100 (Grade F).

N+ Score Breakdown

Ingredient Adequacy0/100

Are key ingredients present at clinically effective doses based on research?

Formula Completeness50/100

Does the product include all expected ingredients for its supplement category?

Label Transparency100/100

Are individual ingredient amounts clearly disclosed without proprietary blends?

Ingredient Diversity71/100

Does the formula include a breadth of beneficial compounds from multiple pathways?

Strengths

  • +Fully transparent label with individual ingredient amounts disclosed
  • +Broad ingredient diversity exceeding category norms

Weaknesses

  • Several ingredients below clinically effective doses

Ingredient Analysis (7 ingredients)

IngredientAmountDose Adequacy
Vitamin D3133.330 IUUnder
Black Pepper (fruit) extract1.670 mgN/A
Hesperidin33.330 mgN/A
Pygeum bark extract33.300 mgN/A
Stinging Nettle leaf extract30.000 mgN/A
Acacetin33.300 mgN/A
Brassaiopsis glomerulata166.670 mgN/A

Clinical ranges based on NIH ODS Fact Sheets and peer-reviewed research. Status indicates whether the amount meets evidence-based thresholds.